Podcasts about triple negative breast cancer

New research presented at ESMO 2025 confirms that datopotamab deruxtecan significantly improves progression-free and overall survival compared with chemotherapy in advanced triple-negative breast cancer, supporting its role as a first-line standard of care. Updated SELECT trial analyses demonstrate that semaglutide reduces major cardiovascular events by 20% independent of weight loss, suggesting cardioprotective mechanisms beyond adiposity reduction. Long-term data show that HPV vaccination has led to dramatic declines in vaccine-type infections and strong herd protection, although global coverage remains suboptimal.

Janice Cowden, retired nurse and patient advocate, shares her remarkable triple negative breast cancer (TNBC) story. Five years following successful treatment for stage one breast cancer in 2011, Janice was diagnosed with a stage 4 metastatic TNBC recurrence. As of today she has 8 years of no evidence of disease (NED) under her belt. She shares how she stumbled upon the cancer community that inspired her to become the advocate she is today and the uncertainty that comes with NED. She also shares how she copes with losing friends in the cancer community through her patient advocacy work. We also have a rapid fire Q&A where she answers questions surrounding various medical terminologies, diagnoses, and more to keep you in the loop. NOTE: There is one clarification from the rapid fire Q&A session. The definition of disease free survival (DFS) is the time from random assignment (used in clinical trials and research studies to assign participants to different groups) to cancer recurrence or death from any cause (Gutman SI, Piper M, Grant MD, et al. 2013).Key Highlights:1. Metastatic breast cancer (MBC) is stage four breast cancer that has spread to distant sites in the body.2. Finding events and communities centered around cancer not only supports cancer patients emotionally and socially, but can also serve as informational hubs. Being proactive in learning about your diagnosis, whether it's through community and/or research on your own time, can help you feel confident with the choices you make. 3. While finding a community of other cancer patients can help, unfortunately this disease means that you will lose friends you make in these settings. It doesn't necessarily get easier, but finding an outlet to cope with such losses is vital to your wellbeing.About our guest:Diagnosed with Stage IV triple negative breast cancer in 2016, five years after an early-stage breast cancer diagnosis, Janice launched into patient advocacy following training through Living Beyond Breast Cancer's (LBBC) Hear My Voice Outreach program in 2017. As a peer-to-peer support and research patient advocate, Janice is passionate about supporting others with metastatic breast cancer, in addition to continually furthering her scientific knowledge base of this disease, treatments, and clinical trials, which she acquires through attending scientific breast cancer conferences and webinars. Janice is involved with several patient-founded and led organizations including PCDI, GRASP, and Project Life MBC. As a trained peer support volunteer, she is founder of an international online peer support group for patients newly diagnosed with MBC. She serves on the Board of Directors for METAvivor Research and Support Inc., and is an Advisory Board member for Project Life MBC. She is an individual member of the Metastatic Breast Cancer Alliance. When she's not busy with advocacy work, Janice enjoys traveling, reading, outdoor activities, and spending time with family, including her husband, two adult children and three grandchildren.Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard, or delay in obtaining, medical advice for any medical condition they may have, and should seek the assistance of their health care professionals for any such conditions.

- Overview of Triple Negative Breast Cancer - The Difference in Triple Negative Breast Cancer for Black/African American Women - Triple Negative Breast Cancer & African American Women - The Role of Surgery - Precision Medicine & Treatment Sequencing - Current Standard of Care - New Treatment Approaches - Clinical Trial Updates - How Clinical Trial Participation Contributes to Treatment Options - Tips to Manage Treatment Side Effects, Symptoms, Neuropathy, Discomfort & Pain - Follow-Up Care Plan - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Follow-Up Appointments - Questions for Our Panel of Experts

- Overview of Triple Negative Breast Cancer - The Difference in Triple Negative Breast Cancer for Black/African American Women - Triple Negative Breast Cancer & African American Women - The Role of Surgery - Precision Medicine & Treatment Sequencing - Current Standard of Care - New Treatment Approaches - Clinical Trial Updates - How Clinical Trial Participation Contributes to Treatment Options - Tips to Manage Treatment Side Effects, Symptoms, Neuropathy, Discomfort & Pain - Follow-Up Care Plan - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Follow-Up Appointments - Questions for Our Panel of Experts

- Overview of Triple Negative Breast Cancer - The Difference in Triple Negative Breast Cancer for Black/African American Women - Triple Negative Breast Cancer & African American Women - The Role of Surgery - Precision Medicine & Treatment Sequencing - Current Standard of Care - New Treatment Approaches - Clinical Trial Updates - How Clinical Trial Participation Contributes to Treatment Options - Tips to Manage Treatment Side Effects, Symptoms, Neuropathy, Discomfort & Pain - Follow-Up Care Plan - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Follow-Up Appointments - Questions for Our Panel of Experts

In this heartfelt conversation, Tonya Combest shares her journey through a breast cancer diagnosis, treatment, and recovery. She discusses the emotional challenges, the importance of community support, and the role of financial planning in navigating her health crisis. Tonya emphasizes the significance of self-exams, the need for reliable medical advice, and the power of empathy in connecting with others facing similar battles. Her story is one of resilience, hope, and the determination to live life fully after cancer.Born and raised in Lubbock, Texas, she and her husband Kevin built a compassionate family business, Combest Family Funeral Homes, serving their community with care. Despite facing a late Stage 3 Triple Negative Breast Cancer diagnosis in 2021, Tonya's strength and faith saw her through rigorous treatments and recovery. Today, she is cancer-free and continues to support others facing similar challenges. Her extensive experience in funeral services and hospice care, combined with her personal journey, makes her an inspiring podcast guest. Join us to hear Tonya's story of overcoming adversity and her insights on community service and end-of-life care.Combest Family Funeral Homes & Crematory | Lubbock, TXTonya Bowen Combest | FacebookGet In Touch With Tonya:

This is a bonus episode of the audio of a Breastcancer.org ⁠⁠⁠⁠webinar⁠⁠⁠⁠. Triple-negative breast cancer (TNBC) is an invasive subtype of breast cancer that can be harder to treat and is more likely to come back. But new research into understanding TNBC is helping some patients find more precise treatment options.  Learn about innovations in immunotherapy, genetic testing, and targeted therapies, why TNBC is different compared to other types of breast cancer, and what gives doctors hope about the future of care for people with TNBC. You'll also hear from two inspiring breast cancer advocates who created TNBC resources for patients after their own diagnosis. Read more about triple-negative breast cancer. Featured Speakers: Maimah KarmoBreast Cancer Advocate and Founder, Tigerlily Roberto Leon-Ferre, MDCo-Leader of the Triple-Negative Breast Cancer Working Group and Associate Professor at Mayo Clinic Evelyn Taiwo, MDHematology and Oncology at New York Presbyterian Brooklyn Methodist Hospital and Associate Professor at Cornell University Kelly ThomasBreast Cancer Advocate and Founder, TNBC Thrivers Marisa Weiss, MDChief Medical Officer, Breastcancer.org

Have a comment or question? Click this sentence to send us a message, and we might answer it in a future episode.Welcome to Season 5, Episode 34 of Winning Isn't Easy. In this episode, we'll dive into the complicated topic of "Breast Cancer and Disability - Understanding the Condition, Its Impact, and Your Claim."Most people assume that a breast cancer diagnosis automatically guarantees Long-Term Disability benefits, but in ERISA claims, it's rarely that simple. Insurance companies often downplay symptoms, ignore treatment side effects, or misclassify your job duties to deny or terminate benefits. The truth is, even early-stage breast cancer can cause lasting physical and cognitive challenges that make full-time work impossible, and your paperwork must tell that story clearly. In this episode of Winning Isn't Easy, disability law expert Nancy L. Cavey explains what it really takes to win a breast cancer Long-Term Disability claim. You'll learn how insurers evaluate cancer-related claims, what evidence they find persuasive, and how to document limitations such as fatigue, pain, cognitive changes, and immune issues so your claim stands strong. We'll also cover how your cancer stage, treatment plan, and occupation affect an insurer's decision, and share a real-world case where benefits were cut off too soon and what it took to fight back. If you or someone you love is facing breast cancer while protecting your financial future, this episode offers the knowledge, strategy, and confidence to take control of your claim. Because in disability law, telling your story the right way isn't just important - it's essential. Winning Isn't Easy, but with the right guidance, it can be done.In this episode, we'll cover the following topics:One - Breast Cancer and Its SymptomsTwo - How Breast Cancer Can Be DisablingThree - Case Example – Lessons From the Kiersman CaseWhether you're a claimant, or simply seeking valuable insights into the disability claims landscape, this episode provides essential guidance to help you succeed in your journey. Don't miss it.Listen to Our Sister Podcast:We have a sister podcast - Winning Isn't Easy: Navigating Your Social Security Disability Claim. Give it a listen: https://wiessdpodcast.buzzsprout.com/Resources Mentioned in This Episode:LINK TO ROBBED OF YOUR PEACE OF MIND: https://mailchi.mp/caveylaw/ltd-robbed-of-your-piece-of-mindLINK TO THE DISABILITY INSURANCE CLAIM SURVIVAL GUIDE FOR PROFESSIONALS: https://mailchi.mp/caveylaw/professionals-guide-to-ltd-benefitsFREE CONSULT LINK: https://caveylaw.com/contact-us/Need Help Today?:Need help with your Long-Term Disability or ERISA claim? Have questions? Please feel welcome to reach out to use for a FREE consultation. Just mention you listened to our podcast.Review, like, and give us a thumbs up wherever you are listening to Winning Isn't Easy. We love to see your feedback about our podcast, and it helps us grow and improve.Please remember that the content shared is for informational purposes only, and should not replace personalized legal advice or guidance from qualified professionals. 

Featuring perspectives from Dr Sara A Hurvitz and Dr Sara M Tolaney, including the following topics: Introduction: View from Outer Space (0:00) Hormone Receptor-Positive Breast Cancer (6:23) HER2-Positive Breast Cancer (40:54) Triple-Negative Breast Cancer (52:48) CME information and select publications

Featuring an interview with Prof Peter Schmid, including the following topics: Response to immunotherapy in breast cancer subtypes (0:00) Tolerability of TROP2 antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC) (3:51) Approaches to therapy for patients with HR-negative HER2-low and HER2-ultralow mBC (13:03) ADC structure and treatment-related adverse events (19:02) Available data from the Phase III ASCENT-04 trial evaluating sacituzumab govitecan with pembrolizumab as first-line therapy for patients with PD-L1-positive advanced triple-negative breast cancer (23:06) Novel ADCs and bispecific antibodies under investigation for mBC (28:30) Comparing datopotamab deruxtecan and sacituzumab govitecan for HR-positive disease (33:01) Clinical investigator perspectives on the Phase III DESTINY-Breast09 trial evaluating first-line trastuzumab deruxtecan with or without pertuzumab versus THP (docetaxel/rastuzumab/pertuzumab) for HER2-positive mBC (35:06) CME information and select publications

Prof Peter Schmid from Barts Cancer Institute in London reviews available efficacy and safety data guiding the optimal management of metastatic triple-negative breast cancer. CME information and select publications here.

Featuring a slide presentation and related discussion from Prof Peter Schmid, including the following topics: Evolution of the therapeutic landscape for metastatic triple-negative breast cancer; age of immunotherapy (0:00) Case: A woman in her early 40s with no actionable mutations (7:29) Evolution of antibody-drug conjugates (ADCs) in the management of metastatic breast cancer (11:13) TROP2-directed ADCs (15:22) Case: A woman in her early 50s with PD-L1-negative, HR-negative, HER2-low de novo metastatic breast cancer (20:21) Novel strategies utilizing approved and investigational ADCs (23:28) Case: A woman in her early 60s with loss of HER2 expression on disease progression (31:39) ADCs in combination with immunotherapy (32:51) CME information and select publications

Send us a text

Becca Johnson shares the sequence of events that led to her breast cancer diagnosis and what happened next. Initial mammograms and consultations showed no clear issues, but persistent symptoms led Becca to push for further testing. When the diagnosis came, she documented every detail and sought support from medical staff and loved ones. Becca describes communicating with her children and organizing her next steps. Faith guided her choices as she incorporated both conventional treatment and alternative approaches. Community support, including fundraising through T-shirt sales featuring meaningful Bible verses, helped cover medical expenses. Becca stresses the importance of research, questioning, and finding a supportive network. Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered 1. How did Becca Johnson first discover she had breast cancer? 2. What was Becca’s initial reaction upon receiving her cancer diagnosis? 3. How did Becca approach telling her children about her diagnosis? 4. What did Becca do after learning about her diagnosis? 5. What specific type of breast cancer was Becca diagnosed with? 6. Did Becca have any known familial risk factors for breast cancer? 7. How did Becca’s faith influence her journey with breast cancer? 8. What role did Becca’s support network play during her diagnosis and treatment? 9. What advice does Becca share for others who receive a cancer diagnosis? 10. What does Becca recommend to those struggling with feelings of isolation after a cancer diagnosis? 11. How did Becca personalize her healing journey (e.g., alternative treatments, lifestyle changes)? Timestamped Overview 00:00 Mammogram Misdiagnosis: Lingering Concerns 06:15 Urgent Call to Doctor 06:52 Seeking Guidance and Self-Discipline 12:11 A Life-Altering Diagnosis 16:04 Urgent Lumpectomy Needed 17:30 Surgery Decision Urgency 21:26 Exodus 14 Revelation 26:10 Spiritual Awakening at 25 27:10 Turning Point: A New Path 31:25 Unique Responses to Cancer TreatmentSee omnystudio.com/listener for privacy information.

Dr Ana C Garrido-Castro and Prof Peter Schmid review patient cases and provide insights regarding the treatment of metastatic triple-negative breast cancer. CME information and select publications here.

Featuring perspectives from Dr Ana C Garrido-Castro and Prof Peter Schmid, including the following topics:  Introduction: Legendary Figures in Breast Cancer Research (0:00) Case: A woman in her early 80s, a current smoker with a history of myocardial infarction and stroke, who develops recurrent triple-negative breast cancer (TNBC) — Justin Favaro, MD, PhD (6:44) Case: A woman in her late 60s with metastatic TNBC and a PD-L1 level of 20% who receives chemotherapy/pembrolizumab followed by sacituzumab govitecan — Priya Rudolph, MD, PhD (25:08) Case: A woman in her late 60s with localized TNBC who develops myocarditis while receiving neoadjuvant chemotherapy/pembrolizumab — Richard Zelkowitz, MD (33:53) Case: A woman in her mid 60s with recurrent ER-negative, HER2-low, PI3K-mutant TNBC — Ranju Gupta, MD (37:49) Case: A woman in her early 60s with recurrent TNBC confined to contralateral neck nodes — Eric H Lee, MD, PhD (42:10) Case: A woman in her early 40s with metastatic TNBC who receives sacituzumab govitecan after multiple lines of chemotherapy — Estelamari Rodriguez, MD, MPH (48:10) Case: A woman in her mid 70s with ER-negative, HER2-low breast cancer who develops an isolated brain metastasis — Dr Gupta (55:02) CME information and select publications

- Overview of Triple Negative Breast Cancer - Fear of Recurrence - Concerns That Cancer May Come Back - Events That May Trigger Fear of Recurrence: Living with Continuing Uncertainty - Promoting Effective Health Care Communication - Making Informed Treatment Choices - Follow-Up Care - Tips for Coping with Fear of Recurrence - Balancing Reality with Stress Management Tips - Using Mind Body Techniques to Cope with Fear of Recurrence - How to Select the Mind Body Techniques That are Best for You - Communicating with Your Health Care Team About Quality-of-Life & Lifestyles Concerns - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & OpenNotes Discussion - Questions for Our Panel of Experts

- Overview of Triple Negative Breast Cancer - Fear of Recurrence - Concerns That Cancer May Come Back - Events That May Trigger Fear of Recurrence: Living with Continuing Uncertainty - Promoting Effective Health Care Communication - Making Informed Treatment Choices - Follow-Up Care - Tips for Coping with Fear of Recurrence - Balancing Reality with Stress Management Tips - Using Mind Body Techniques to Cope with Fear of Recurrence - How to Select the Mind Body Techniques That are Best for You - Communicating with Your Health Care Team About Quality-of-Life & Lifestyles Concerns - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & OpenNotes Discussion - Questions for Our Panel of Experts

- Overview of Triple Negative Breast Cancer - Fear of Recurrence - Concerns That Cancer May Come Back - Events That May Trigger Fear of Recurrence: Living with Continuing Uncertainty - Promoting Effective Health Care Communication - Making Informed Treatment Choices - Follow-Up Care - Tips for Coping with Fear of Recurrence - Balancing Reality with Stress Management Tips - Using Mind Body Techniques to Cope with Fear of Recurrence - How to Select the Mind Body Techniques That are Best for You - Communicating with Your Health Care Team About Quality-of-Life & Lifestyles Concerns - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & OpenNotes Discussion - Questions for Our Panel of Experts

Send us a textEpisode #17 // Season:2025Our Founder & CEO, Luba Sasowski, celebrated a hard-fought win: the successful close of Bryght's 2020-2022 lawsuit. What makes this milestone even more powerful? Luba was undergoing treatment for Triple Negative Breast Cancer at the very same time.This throwback video captures her sitting down with our legal team sharing not only how we won, but also the lessons every small business needs to hear. Because the truth is, a lawsuit can happen to anyone.Three years later, this anniversary isn't just about surviving a case it's about thriving as a brand, staying resilient, and shining Bryghter than ever.  **The information provided in this video does not, and is not intended to, constitute legal advice or a contract; instead, all information, content, and materials available in this video are for general informational purposes only and based on publicly available information. Information in this video does not constitute the most up-to-date legal or other information. The video description may contain links to other third-party websites. Such links are only for the convenience of the viewer, user, or browser; Gelber Schachter & Greenberg, P.A., and its employees do not recommend or endorse the contents of any website. All opinions of Bryght are it's own and do not represent the opinions of Gelber Schachter & Greenberg, P.A.. **Support the show-----Our intro and outro music is made by Ashley from Lullaby The Fear Podcast. Listen to Lullaby here: https://lullabythefearpodcast.com/Special offer on Chippendale tickets! Use code BRYGHT25 for 25% off tickets to The Chippendales on Ticketmaster.Use code BRYGHT25 to get 25% OFF your tickets now!Sign up for Emails: https://promotions.lpage.co/campaigns/2789115See our trade show schedule: https://bryghtenup.com/pages/eventsFree online webinars: https://bryghtenup.com/pages/webinarStart Your Own Podcast for FREE With Buzzsprout Using Our Link and Get $20!! https://www.buzzsprout.com/?referrer_id=739373Follow us on social media @betweenbothcheekspodcastEmail us at podcast@bryghtenup.com

Did you know not all breast cancers can be treated the same way? In this episode of the HR on the Offensive podcast host Chris Howard, a member from our CSR team Natalie Berkoff, and guest Robin Woolcock, chairman of the UK charity for Triple Negative Breast Cancer (TNBC), pulls back the curtain on one of the most aggressive and least understood forms of the disease. The UK charity for Triple Negative Breast Cancer is one of LACE Partners' chosen charities that we choose to support and to us, support is more than charitable donations, but it is also about raising awareness. That is what we hope to do with today's podcast. `

- American Society of Clinical Oncology (ASCO) 2025 Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Young Adults & Older Adult Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort, Quality of Life & Pain - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- American Society of Clinical Oncology (ASCO) 2025 Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Young Adults & Older Adult Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort, Quality of Life & Pain - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- American Society of Clinical Oncology (ASCO) 2025 Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Young Adults & Older Adult Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort, Quality of Life & Pain - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

Send us a text

In today's episode, we had the opportunity to speak with Henry M. Kuerer, MD, PhD, FACS, CMQ, about the potential to safely omit surgery in a subset of patients with early-stage HER2-positive or triple-negative breast cancer who achieve a pathologic complete response (pCR) following neoadjuvant systemic therapy. Dr Kuerer is a professor of breast surgical oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. In our conversation, Dr Kuerer reviewed the rationale behind a prospective phase 2 clinical trial (NCT02945579) testing image-guided vacuum-assisted core biopsy to identify patients with no residual disease after neoadjuvant therapy. He outlined the strict technical and eligibility criteria that enabled accurate detection of pCR—including tumors downsizing to less than 2 cm and biopsy of at least 12 cores from the tumor bed—and discussed why this biopsy-based approach may be more reliable than standard surgery in detecting residual disease. He also highlighted the broader clinical implications of the findings, noting that patients with biopsy-confirmed pCR may proceed directly to radiotherapy and avoid breast surgery altogether.

Host Melissa Berry sits down with LaToya Bolds-Johnson — Physician Associate, triple negative breast cancer survivor, and passionate clinical trials advocate. With her experience as both a healthcare provider and a patient, Latoya offers a meaningful and insightful perspective on clinical trials and how they can transform cancer treatment. In this episode, LaToya shares her personal journey navigating breast cancer treatment and the challenges of finding the right clinical trial. They discuss the critical need for greater diversity in clinical trial participation, and how her involvement created a “medical trust fund” for her daughters' futures. LaToya also discusses how we can shift the mindset around clinical trials from being seen as a last resort to a standard of care, helping patients advocate for themselves and make informed choices. If you're newly diagnosed, considering treatment options, or want to learn how clinical trials can offer hope and opportunity, this episode is a must-listen!  

Host Melissa Berry sits down with Melissa Eppard, a triple negative breast cancer survivor and co-founder of Upstate Mary, a wellness brand focused on CBD-infused intimacy products. They talk about Melissa's personal breast cancer experience and the challenges many patients face with intimacy during and after treatment. Their conversation highlights the importance of addressing issues like vaginal dryness and the need for lubrication, which are often misunderstood, overlooked, and surrounded by shame. Melissa shares how CBD can help improve comfort and sexual wellness, while normalizing these conversations and taking the shame away. They also discuss the pressures both cancer survivors as well as their partners can feel around intimacy and the power of community support in reclaiming confidence and connection after cancer. This episode offers honest insights and encourages open conversations about sexual health for cancer survivors and their partners.

Clinical investigators discuss available data guiding the management of HER2-positive, triple-negative and localized breast cancer.  CME information and select publications here.

Featuring perspectives from Dr Aditya Bardia, Dr Virginia F Borges, Dr Harold J Burstein and Dr Joyce O'Shaughnessy, including the following topics: Introduction (0:00) HER2-Positive Breast Cancer — Dr O'Shaughnessy (3:13) Triple-Negative Breast Cancer — Dr Bardia (32:56) Personalizing Adjuvant Therapy for Patients with HR-Positive Breast Cancer — Dr Borges (57:35) Current Role of CDK4/6 Inhibitors in the Localized Setting — Dr Burstein (1:25:15) CME information and select publications

It's been known for many years that Black women are twice as likely as white women to be diagnosed with triple-negative breast cancer. If diagnosed with this type of breast cancer, Black women are also more than twice as likely to die from the disease than women of other races and ethnicities. Researchers have been studying a number of factors that may play a role in these disparities. Dr. Sanchita Bhatnagar's research has found that cells that have too much TRIM37 protein are much more likely to become cancerous. She and her colleagues also have found that the breast tissue of Black women are much more likely to have high levels of TRIM37. Listen to the episode to hear Dr. Bhatnagar explain: how she began studying the TRIM37 gene how a variant in the TRIM37 gene that causes more of the TRIM37 protein to be made is more common in Black women that white women how a medicine that targets the TRIM37 protein could help stop triple-negative breast cancer from metastasizing next steps for her research

In this special episode, I sit down with Ricki Fairley of TOUCH, The Black Breast Cancer Alliance and Hayley Dinerman of the Triple Negative Breast Cancer Foundation to discuss the latest advancements in TNBC research, including key takeaways from SABCS 2024, new immunotherapy and targeted therapies, and the impact of the AACR research grant. We also explore efforts to address racial disparities, upcoming awareness initiatives, and how you can get involved. Don't miss this insightful conversation about the future of TNBC treatment and advocacy. Thank you to Merck, Daiichi-Sankyo, Gilead, Pfizer, and Lilly for making this episode possible!  

About 10% to 15% of breast cancers are triple-negative. This means they don't have receptors for the hormones estrogen or progesterone, and don't have too many HER2 proteins. So, hormonal therapy medicines and medicines that target the HER2 protein aren't effective against triple-negative breast cancer.  Chemotherapy and immunotherapy are commonly used to treat triple-negative disease. But scientists are working diligently to develop new treatments that are more precise and targeted.  Triple-negative breast cancer expert Dr. Lisa Carey explains the latest research. Listen to the episode to hear Dr. Carey discuss: the two main areas of research on triple-negative breast cancer what antibody-drug conjugates are and their potential for treating triple-negative disease  the benefits of combining antibody-drug conjugates with immunotherapy the features of triple-negative breast cancer that make researchers think a vaccine for it is possible

Dinah McClymonds shares her journey with triple negative breast cancer and how regular mammograms detected her condition. She elaborates on her 2016 diagnosis and subsequent chemotherapy, surgery, and radiation, until she completed treatment a year later. Dinah had a positive experience with the medical care she received but acknowledges that many women lack such access. Her conversation with Dorothy highlights that early detection can significantly impact outcomes, even for those without a family history of the disease. She stresses the importance of mammograms and the need for broader access to these screenings, especially for uninsured women. Dinah also touches on her role as the chair for the 2025 Everything’s Coming Up Roses Luncheon supporting The Rose. Her background in fundraising and volunteering shapes her efforts to increase awareness and resources for those in need. Subscribe to Let’s Talk About Your Breasts wherever you get your podcasts and consider making a donation at therose.org. Key Questions Answered 1.) What prompted Dinah McClymonds to discuss breast cancer treatment and medical care? 2.) When and how was Dinah McClymonds's breast cancer diagnosed? 3.) How did her age and ethnicity influence her breast cancer treatment and prognosis? 4.) Did Dinah inform her family about her diagnosis, and how did genetic testing play a role for her identical twin? 5.) What is Dinah's message regarding early breast cancer detection and access to treatment? Timestamped Overview 00:00 Dinah to chair 2025 breast cancer luncheon. 03:33 Involvement in volunteer work with Kappa Alpha Theta. 09:06 Access to breast cancer treatment varies widely. 10:39 Challenging cancer diagnosis disrupts vacation plans. 14:06 Mammogram detected breast cancer, no symptoms noticed. 18:00 Unexplained triple negative, not hormonal, just fluke. 21:59 Effects of breast cancer treatment on body. 23:43 Accepting aging and medical treatment's inevitable impact. 29:04 Supporting access to early cancer detection and treatment. 30:11 Thank you for being our chair today.See omnystudio.com/listener for privacy information.

A young mom discovers a lump and learns she has triple negative breast cancer. She shares her journey and the supports she found from family, friends and faith.

It is Triple Negative Breast Cancer Day – an annual opportunity to bring more awareness to this aggressive type of breast cancer that is difficult to treat because it lacks an estrogen, progesterone and HER2 receptor. It primarily affects younger women and Black women and can spread quickly and be deadly if left untreated for too long. Treatment for TNBC used to include the toughest forms of chemotherapy, with debilitating side effects – but we've come a long way in how we treat patients with Triple Negative Breast Cancer so their outcomes are better. Today, we are speaking with Dr. Heather McArthur of UT Southwestern. She is a former Susan G. Komen grantee, Professor and the Komen Distinguished Chair in Clinical Breast Cancer Research. Dr. McArthur has been working on a Phase 3 clinical trial called KEYNOTE-522, which is testing whether a specific immunotherapy drug improves overall survival for people with high-risk early Triple Negative Breast Cancer. Dr. McArthur, along with her colleagues, are trying to determine if all people with this type of breast cancer truly need the drug, and if not, who would most benefit from taking it.

It's all about love, and we need a lot of it, now more than ever. Please join me in welcoming my friend, Jennifer Greenhut aka @GreenhutTheBand, Stage IV Triple-Negative Breast Cancer Survivor, author, “Everyone Needs a Larry, Love with a Twist of Cancer,” and founder of the @ZeroNegativeOrg. Jennifer will talk about her journey with cancer, how she discovered she had Breast Cancer in the midst of trying to have a baby, and what ultimately saved her. She feels grateful, and for Valentine's Day, she's talking about spreading love and support for cancer patients with her “love totes” from @lovezeronegative, which are beautiful and proceeds support cancer research at the Johnson Cancer Center Foundation at UCLA. Oh, and there's more. Jennifer's parents and sister lost their homes in the Palisades fires, and they've all been pivoting to dealing with that tragedy, and she says there's lesson in all of that, too. And wait until you hear what survived!! Please join me on all video and audio platforms of #DeborahKobyltLIVE, and invite your friends, too. I'm your host, #DeborahZaraKobylt, and it's my pleasure to welcome you here

Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. To Get Cheryl's Book; https://www.amazon.com/dp/0190636165?linkCode=ssc&tag=onamzchefajsh-20&creativeASIN=0190636165&asc_item-id=amzn1.ideas.1GNPDCAG4A86S&ref_=aip_sf_list_spv_ofs_mixed_d_asin Cheryl Krauter,MFT an Existential Humanistic psychotherapist with 45 years of experience in the field of depth psychology and human consciousness. With her background in theater arts, working with performing artists, visual artists and creative people has inspired her. Her diagnosis of Triple Negative Breast Cancer in 2007 brought her into the world of psycho-oncology when she was asked to serve as a psychological consultant on a hospital survivorship plan task force. Committed to serving the community, she is a former board member of the Women's Cancer Resource Center in Oakland, California. She works with people who have been diagnosed with cancer and other life-threatening illnesses, their partners, family members, and caregivers from diagnosis to end of life care. She has published two books: Surviving the Storm: A Workbook for Telling Your Cancer Story (Oxford University Press 2017) and Psychosocial Care of Cancer Survivors: A Clinician's Guide and Workbook for Providing Wholehearted Care (Oxford University Press 2018). Her book Odyssey of Ashes: A Memoir of Love, Loss, and Letting Go, She Writes Press, was released in July 2021. Her piece With This Ring is published in Loss and Grief: Personal Stories of Doctors and Other Healthcare Professionals (Oxford University Press 2022). Cheryl has been a member of the American Psychosocial Oncology Society (APOS)and the International Psychosocial Oncology Society (IPOS) since 2014. She has served as the Director of Communications for the American Psychosocial Oncology Society since 2023 and was honored to receive the APOS Distinguished Public Service Award in 2022. Cheryl has given workshops and classes at The Women's Cancer Resource Center (Oakland, CA), The Cancer Support Community (Walnut Creek and Los Angeles, CA), University of California, Berkeley, University of California, San Francisco Cancer Center, The American Psychosocial Oncology Society, San Francisco State University, Casting for Recovery, Swedish Cancer Center (Seattle WA), Northern California Group Psychotherapy Society, Alta Bates Hospital (Berkeley, CA) You may find resources, podcasts, interviews, articles, webinars on her website. www.cherylkrauter.com Surviving the Storm: Finding Resilience and Discovering Possibility When Facing a Cancer Diagnosis “It only takes a few seconds to receive the news that you have been diagnosed with cancer. Yet, from that point on your world has been changed forever. You enter a vast terrain of uncertainty, isolation and insecurity when you finish treatment for cancer. What is it like to face daily life now that you are finished with treatment? Fear of recurrence, anxiety and depression related to uncertainty, along with loss and financial difficulties, as well as concerns around sexuality are all a part of this new territory. You may feel alone and distressed. You have all the knowledge within you to understand and create your own healing but sometimes you need guidance to help you find where you are and support you in discovering where you want to go.” Excerpt from Surviving the Storm: A Workbook for Telling Your Cancer Story by Cheryl Krauter, MFT Let's build a conversation on how those who have been diagnosed with cancer can find ways to thrive and engage meaningfully in their lives as they navigate their diagnosis.

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Virginia Kaklamani from the UTHealth San Antonio MD Anderson Cancer Center to discuss the latest advances in the treatment of triple negative breast cancer (TNBC) as we kick off 2025. •⁠  ⁠The treatment paradigms for early-stage TNBC, including the role Sacituzumab and radiation therapy. •⁠  ⁠Insights from the SABCS 2024 conference, focusing on the keynote 522 regimen and its implications for neoadjuvant treatment. •⁠  ⁠The management of locally advanced and metastatic TNBC, including the use of immunotherapy and the importance of PD-L1 testing. •⁠  ⁠Strategies for managing toxicities associated with treatments like sacituzumab and T-DXd. Whether you're a healthcare professional or someone interested in the latest in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! Key Takeaways: •⁠  ⁠Current standard of care for locally advanced TNBC. •⁠  ⁠The significance of chemotherapy and immunotherapy in treatment plans. •⁠  ⁠Managing toxicities in metastatic disease. Stay tuned for more discussions on treatment algorithms, FDA approvals, and clinical pearls in oncology! YouTube: https://youtu.be/GfROoYPVb_8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from January 25-31, 2025.

Featuring perspectives from Dr Lisa Carey and Dr Rita Nanda, including the following topics: Introduction (0:00) Patient Videos and Clinical Investigator Survey (3:26) San Antonio Breast Cancer Symposium (SABCS®) Report — Education Session on Antibody-Drug Conjugates (26:03) Patient Videos and Clinical Investigator Survey (43:27) SABCS Report — Abstracts of Interest (55:56) Patient Videos and Clinical Investigator Survey (56:27) CME information and select publications

Dr Lisa A Carey from UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from the University of Chicago in Illinois address commonly asked questions from patients diagnosed with metastatic triple-negative breast cancer. CME information and select publications here

Dr Lisa A Carey from UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from the University of Chicago in Illinois address commonly asked questions from patients diagnosed with metastatic triple-negative breast cancer. CME information and select publications here

In this enlightening episode of the Patient From Hell, host Samira Daswani interviews Dr. Sara Tolaney, a leading oncologist specializing in breast cancer. They delve into the evolving landscape of triple-negative breast cancer (TNBC), exploring advancements in treatment, from targeted therapies to immunotherapy, and the challenges faced by patients in both early-stage and metastatic settings. With her characteristic warmth and expertise, Dr. Tolaney provides actionable insights for patients and caregivers, offering hope and understanding in navigating this complex diagnosis. Key Highlights: 1. A New Paradigm in Early-Stage TNBC Treatment: Dr. Tolaney explains how neoadjuvant chemotherapy combined with immunotherapy has revolutionized outcomes, achieving pathologic complete response rates above 60%. 2. Metastatic TNBC Advances: The discussion highlights the critical role of biomarker testing and the introduction of innovative therapies like antibody-drug conjugates, providing extended survival for many patients. 3. Empowering Patient Symptom Management: The episode underscores the importance of patient-reported outcomes and emerging tools like health apps to enhance self-management and real-time support for side effects. About our guest: Sara Tolaney, MD, MPH is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and is internationally recognized for her research and education leadership in breast cancer. She also serves as Associate Director of the Susan F. Smith Center for Women's Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. Dr. Tolaney received her undergraduate degree from Princeton University and her medical degree from UC San Francisco. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained her Masters in Public Health from Harvard School of Public Health. Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She is the author of over 150 peer-reviewed publications with manuscripts included in many prestigious journals such as the New England Journal, Lancet Oncology, Journal of Clinical Oncology, and JAMA Oncology. Key Moments: At 8 minutes: "It used to be that if someone had a triple negative breast cancer, we would often take someone to surgery and then after surgery give them some chemotherapy to kill any stray cells that might've gotten into the bloodstream and integrate radiation as needed. But we've really changed our approach very dramatically over the last few years where we've learned that if someone has an early stage, stage two or three triple negative breast cancer, it is actually very critical that they not go to upfront surgery, but in fact get chemotherapy with immunotherapy prior to surgery." Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics:  Introduction (0:00) Stages of Triple-Negative Breast Cancer (TNBC); Recurrence After Adjuvant Treatment (5:28) Long-Term Outcomes with Metastatic TNBC (11:55) Side Effects and Complications of Treatment (24:42) Dose Reduction (30:27) Working While Receiving Treatment (32:24) Support for Minor Children and Grandchildren (37:12) Second Opinions and Self Advocacy (42:53) Recording Clinic Visits; Complementary Therapies; Nutrition (48:38) Living Wills and Advanced Directives (55:41) Please take our survey

For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill and Dr Rita Nanda from The University of Chicago to discuss the patient experience associated with the diagnosis and treatment of metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. Select publications here (https://www.researchtopractice.com/PatientProject2024/mTNBCPatients).

Triple-negative breast cancer accounts for around 15% of breast cancers. Zhi-Ming Shao, MD, of Fudon University, joins JAMA Oncology Editor in Chief and JAMA Deputy Editor Nora Disis, MD, to discuss "Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients with Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial." Related Content: Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer

Learn how to kick out chemo symptoms with fitness led by Carly Fauth of Fit Fun Carly. “Fit Fun Carly” has taught over 4,000 fitness classes of all types and has dedicated her life to EVERYbody find joy and fun in fitness. And then, in February, she was diagnosed with Triple Negative Breast Cancer. She pushed through 16 weeks of aggressive chemo (and started her podcast: "Chemo Coffee Coffee Talk" on Spotify right from the chemo chair!) and discovered just how much exercise can kick out miserable chemo symptoms—even when it's the last thing you want to do! Tune it in to learn how to be “fit for the fight” and discover joy in movement!  For more tools to support your healing journey, grab a copy of Heal Breast Cancer Naturally—a comprehensive guide that includes supportive supplements and holistic processes for healing, including insights for Triple Negative Breast Cancer like Carly experienced. Or explore our Matcha Green Tea or DIM supplements, specifically chosen for their ability to support detoxification and hormone balance during recovery.

In December 2023, Charity Kelchen of Iowa was given only weeks to live, facing the devastating reality of stage 4 triple-negative breast cancer, compounded by a painful, fungating tumor. Placed on hospice care, she endured months of severe bleeding and blood loss until doctors removed an 8-pound tumor from her chest. But her battle was far from over—new, aggressive tumors emerged, forcing her through 40 grueling days of radiation. Amid the relentless fight, Charity turned to cannabis oil, an unconventional yet powerful tool in her recovery. On October 10th, 2024, she received the news she had fought so hard for—a clean scan. Visit our website: CannabisHealthRadio.comFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover